Regulation of cGAS-STING pathway with inhalable nanozyme in acute lung injury.
Summary
This preclinical study shows that inhalable CoAl-LDH nanozyme scavenges ROS and, uniquely, binds damaged DNA to suppress cGAS-STING signaling, dampening inflammatory cascades in ALI. Co-loading with the cGAS-STING inhibitor C176 further reduces inflammation and tissue injury, suggesting a targeted nanotherapeutic strategy for ARDS.
Key Findings
- CoAl-LDH (CAL) nanosheets exhibit strong ROS scavenging and mitigate ALI inflammation.
- CAL binds damaged DNA and inhibits cGAS-STING–mediated inflammatory signaling (first demonstration).
- Co-incorporation of cGAS-STING inhibitor C176 enhances anti-inflammatory effects and reduces lung tissue damage.
Clinical Implications
While preclinical, targeting cGAS-STING via inhalable nanozymes could complement lung-protective ventilation by directly attenuating innate immune overactivation in ARDS.
Why It Matters
It identifies a previously unrecognized mechanism—nanozyme binding to damaged DNA to block cGAS-STING—and demonstrates inhalable delivery as a translationally attractive modality for ARDS.
Limitations
- Preclinical study without human subjects; translational safety and dosing remain untested.
- Sample size and long-term toxicity/clearance data are not specified in the abstract.
Future Directions
Conduct GLP toxicology, pharmacokinetics, and aerosol performance studies, followed by early-phase trials to assess safety and biomarker modulation (cGAS-STING) in ARDS.
Study Information
- Study Type
- Case series
- Research Domain
- Treatment
- Evidence Level
- V - Preclinical experimental study without human subjects
- Study Design
- OTHER